Concomitant Use of VA-ECMO and Impella Support for Cardiogenic Shock.

Background: VA-ECMO with concomitant Impella support (ECpella) is an emerging treatment modality for cardiogenic shock (CS). Survival outcomes by CS etiology with ECpella support have not been well-described.
Methods: This study was a retrospective, single-center analysis of patients with cardiogenic shock due to acute myocardial infarction (AMI-CS) or decompensated heart failure (ADHF-CS) supported with ECpella from December 2020 to January 2023. Primary outcomes included 90-day survival post-discharge and destination after support. Secondary outcomes included complications post-ECpella support.
Results: A total of 44 patients were included (AMI-CS, n = 20, and ADHF-CS, n = 24). Patients with AMI-CS and ADHF-CS had similar survival 90 days post-discharge ( p = .267) with similar destinations after ECpella support ( p = .220). Limb ischemia and acute kidney injury occurred more frequently in patients presenting with AMI-CS ( p=. 013; p = .030). Patients with initial Impella support were more likely to survive ECpella support and be bridged to transplant ( p =.033) and less likely to have a cerebrovascular accident (p =.016). Sub-analysis of ADHF-CS patients into acute-on-chronic decompensated heart failure and de novo heart failure demonstrated no difference in survival or destination.
Conclusion: ECpella can be used to successfully manage patients with CS. There is no difference in survival or destination for AMI-CS and ADHF-CS in patients with ECpella support. Patients with initial Impella support are more likely to survive ECpella support and bridge to transplant. Future multicenter studies are required to fully analyze the differences between AMI-CS and ADHF-CS with ECpella support.
Competing Interests: Disclosures Dr. Kaczorowski received consultant and speaking fees for Medtronic and Abiomed as well as intellectual property interest in ECMOTek, LLC. Dr. Hickey has received speaking fees for Abiomed. Wyatt Klass receives consultant fees for Boston Scientific. There are no direct conflicts of interest as it relates to this manuscript. Other authors of this manuscript have no conflicts of interest to disclose.